Exact Mass: 1009.3617919999999
Exact Mass Matches: 1009.3617919999999
Found 12 metabolites which its exact mass value is equals to given mass value 1009.3617919999999,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(3r)-27-Amino-3-Hydroxy-2,2-Dimethyl-4,8,14-Trioxo-12-Thia-5,9,15,19,24-Pentaazaheptacos-1-Yl [(2s,3r,4s,5s)-5-(6-Amino-9h-Purin-9-Yl)-4-Hydroxy-3-(Phosphonooxy)tetrahydrofuran-2-Yl]methyl Dihydrogen Diphosphate
C33H62N11O17P3S (1009.3258552000001)
PubChem CID: 24763004; (Acyl-CoA); [M+H]+
C33H62N11O17P3S (1009.3258552000001)
[(3R,5S,6S)-3-[(2S,3S,5S)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-4,5-diacetyloxy-6-[(2S,4R,5S)-1,2,4,5,6-pentaacetyloxyhexan-3-yl]oxyoxan-2-yl]methyl acetate
[(3R,5S,6S)-3-[(2R,3R,5R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-4,5-diacetyloxy-6-[(2R,4R,5S)-1,2,4,5,6-pentaacetyloxyhexan-3-yl]oxyoxan-2-yl]methyl acetate
SJF-0628
SJF-0628 (compound 512) is a PROTAC RAF degrader. SJF-0628 induces targeted degradation of BRAF mutants (DC50: 5.4 nM, 4.64 nM, 15.5 nM, 2.11 nM, 63.9 nM for BRAF V600E, V600K, G464V, G469A, K601E respectively). SJF-0628 has anti-tumor activity. SJF-0628 can be used for research of disorders that result from aggregation or accumulation of RAF, or the constitutive activation of RAF[1].
n-[(2s,5s,11s,12s,15s,18s,21r)-15-(3-carbamimidamidopropyl)-2-[(4-chlorophenyl)methyl]-6,13,16,21-tetrahydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,9,22-trioxo-8-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-hydroxy-3-(sulfooxy)propanimidic acid
C43H60ClN9O15S (1009.3617919999999)
2-({[(2s,3r,4r,5r)-5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]tetradecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid
2-({[(2s,3r,4r,5r)-5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]-12-methyltridecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid
2-({[5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]tetradecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid
n-[15-(3-carbamimidamidopropyl)-2-[(4-chlorophenyl)methyl]-6,13,16,21-tetrahydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,9,22-trioxo-8-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-hydroxy-3-(sulfooxy)propanimidic acid
C43H60ClN9O15S (1009.3617919999999)